Science to Protect Tomorrow
Welcome to IASO Therapeutics
A Breakthrough Synthetic Vaccine Platform
Vaccines have protected humankind from many deadly infections including smallpox, yellow fever, and tetanus, saving millions of lives. However, the rampage of the COVID-19 over the world serves as a painful reminder of the lack of effective vaccines against many other diseases. Novel technologies that can be readily deployed for new vaccines, especially against newly emerged pathogens, are urgently needed.
Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases.
Platform Technology
IASO integrates precision synthetic antigens with a powerful mQβ VLP carrier, eliciting robust, durable, and antigen-focused immunity. Our platform enables:
Mutant Qβ Platform
Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest when compared to conjugate carrier proteins like Keyhole Limpet Hemocyanin, diphtheria toxoid, tetanus toxoid, and cross reactive material-197 (CRM-197).
Our Mission
IASO Therapeutics is redefining infectious disease prevention by building a synthetic antigen vaccine platform to combat the escalating threat of antimicrobial resistance. Our goal is to deliver broad-spectrum vaccines that offer rapid protection, room-temperature stability, and global scalability.
Recent Company News
Iaso Therapeutics to Showcase Novel mQβ Vaccine Platform at 2026 World Vaccine Congress
Iaso Therapeutics will present at the 2026 World Vaccine Congress on Tuesday, March 31. President and CEO Robert Forgey, MS, MBA, will provide an overview of Iaso’s technology and commercial strategy during his live presentation at the Innovator Showcase.
Iaso Therapeutics Develops Next Generation of Vaccines
In an article in the Lansing Economic Area Partnership news, Iaso was highlighted for its work with next generation of vaccines. This is an excerpt from the article written by Genesis Lodise. A small [...]
